Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of June 2022

 

Commission File Number:  001-40712

 

Cardiol Therapeutics Inc.

(Name of registrant)

 

602-2265 Upper Middle Road East

Oakville, Ontario L6H 0G5

Canada

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

¨   Form 20-F

x   Form 40-F

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

 

 

 

 

 

 

INCORPORATION BY REFERENCE

 

Exhibit 99.1 and Exhibit 99.2 to this report on Form 6-K are hereby incorporated by reference as Exhibits to the Registration Statement on Form F-10 of Cardiol Therapeutics Inc. (File No. 333-262342), as amended and supplemented.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	CARDIOL THERAPEUTICS INC.
	(Registrant)
Date:  June 9, 2022	By:	/s/ Chris Waddick
		Name:	Chris Waddick
		Title:	Chief Financial Officer

 

 

 

 

Form 6-K Exhibit Index

 

Exhibit Number		Document Description
99.1		Consent of Borden Ladner Gervais LLP dated June 9, 2022
99.2		Equity Distribution Agreement dated June 9, 2022
99.3		Press Release dated June 9, 2022